Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Watkins

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphomaHans Reiser, Jianying Wang, Lee Chong, et al.
Circulation. Genomic and Precision Medicine|May 13, 2020
Metabolic Dysregulation of the Lysophospholipid/Autotaxin Axis in the Chromosome 9p21 Gene SNP rs10757274Sven W Meckelmann, Jade I Hawksworth, Daniel White, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infectionScott E Lazerwith, Willard Lew, Jennifer Zhang, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymeraseMartijn Fenaux, Stacey Eng, Stephanie A Leavitt, et al.
Journal of Medicinal Chemistry|November 21, 2024
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary FibrosisDoris T Tang, Zhimin Du, Kin S Yang, et al.
The Lancet. Global Health|April 15, 2022
Neonatal sepsis and mortality in low-income and middle-income countries from a facility-based birth cohort: an international multisite prospective observational studyRebecca Milton, David Gillespie, Calie Dyer, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphomaHans Reiser, Jianying Wang, Lee Chong, et al.
Circulation. Genomic and Precision Medicine|May 13, 2020
Metabolic Dysregulation of the Lysophospholipid/Autotaxin Axis in the Chromosome 9p21 Gene SNP rs10757274Sven W Meckelmann, Jade I Hawksworth, Daniel White, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery of GS-9669, a thumb site II non-nucleoside inhibitor of NS5B for the treatment of genotype 1 chronic hepatitis C infectionScott E Lazerwith, Willard Lew, Jennifer Zhang, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV InhibitorsScott E Lazerwith, Gina Bahador, Eda Canales, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2012
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymeraseMartijn Fenaux, Stacey Eng, Stephanie A Leavitt, et al.
Journal of Medicinal Chemistry|November 21, 2024
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary FibrosisDoris T Tang, Zhimin Du, Kin S Yang, et al.
The Lancet. Global Health|April 15, 2022
Neonatal sepsis and mortality in low-income and middle-income countries from a facility-based birth cohort: an international multisite prospective observational studyRebecca Milton, David Gillespie, Calie Dyer, et al.
Pageof 5